LIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results

Bulletin Express

04/08

Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.

The notification, released from Zhuhai on 8 April 2026, lists the current Board composition: • Executive Director: Tang Yanggang (Vice Chairman) • Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng • Employee Representative Director: Ran Yongmei • Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao

Investors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1182294159"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182294159\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182294159?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182294159","market":"hk","top_or_hot":-1,"title":"LIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.</p>\n<p>The notification, released from Zhuhai on 8 April 2026, lists the current Board composition:\n• Executive Director: Tang Yanggang (Vice Chairman)  \n• Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng  \n• Employee Representative Director: Ran Yongmei  \n• Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao</p>\n<p>Investors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-04-08 17:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.</p>\n<p>The notification, released from Zhuhai on 8 April 2026, lists the current Board composition:\n• Executive Director: Tang Yanggang (Vice Chairman)  \n• Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng  \n• Employee Representative Director: Ran Yongmei  \n• Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao</p>\n<p>Investors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"麗珠醫藥","start_time":0,"source_url":"","article_id":"1182294159","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182294159","pubTimestamp":1775638900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药定于2026年4月23日召开董事会批准第一季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.\nThe notification, released from Zhuhai on 8 April 2026, lists the current Board composition:\n• Executive Director: Tang Yanggang (Vice Chairman)  \n• Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng  \n• Employee Representative Director: Ran Yongmei  \n• Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao\nInvestors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}